One meta-analysis of randomized clinical trials (RCTs) reported noninferiority of tirzepatide for cardiovascular safety compared with the control groups,11 though the included studies were highly heterogenous regarding their comparators (ie, placebo, insulin, GLP-1 RA) and trial participant characteristics, thus precluding a solid conclusion.11 Notably, there is a lack of studies directly comparing tirzepatide with GLP-1 RAs, thereby necessitating further investigation in this context. Here, GCG is linked to rheumatoid arthritis.